DSIP vs Pinealon
DSIP (Endogenous neuropeptide (Delta Sleep-Inducing Peptide, nonapeptide)) and Pinealon (Short synthetic peptide bioregulator (tripeptide)) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | DSIP | Pinealon |
|---|---|---|
| Compound class | Endogenous neuropeptide (Delta Sleep-Inducing Peptide, nonapeptide) | Short synthetic peptide bioregulator (tripeptide) |
| Research category | Cognitive & Nootropic | Cognitive & Nootropic |
| Length (amino acids) | 9 amino acids | 3 amino acids |
| Molecular weight | 848.8 g/mol | 418.4 g/mol |
| Half-life | ~7 minutes (serum) | Not documented |
| Origin | Delta Sleep-Inducing Peptide (DSIP) was originally isolated in the 1970s from the cerebral venous blood of rabbits during induced sleep by researchers in Switzerland. It is a naturally occurring neuropeptide. | Pinealon is a synthetic short peptide (peptide bioregulator) developed within the Russian school of peptide bioregulator research associated with the St. Petersburg Institute of Bioregulation and Gerontology. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How DSIP works
DSIP is a neuropeptide historically associated with the promotion of delta-wave (slow-wave) sleep, though its exact receptor and mechanism of action remain poorly defined. Research has explored roles in stress modulation, neuroendocrine regulation, and antioxidant effects. Findings across studies have been inconsistent, and its physiological function is still not fully understood.
How Pinealon works
Pinealon is a short peptide reported in the Russian bioregulator literature to have neuroprotective and gene-regulatory effects, with proposed activity related to modulation of gene expression in neuronal cells. Its detailed molecular mechanism is not well established outside of this research tradition, and independent Western validation is limited.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
DSIP
Pinealon
What sets each apart
DSIP
DSIP is a naturally occurring sleep-associated neuropeptide with an undefined mechanism, distinguishing it from the cognition-focused synthetic peptides in this class.
Pinealon
Pinealon belongs to the ultra-short peptide bioregulator category, unlike the longer or growth-factor-derived peptides elsewhere in this class.
Frequently asked questions
What is DSIP (delta sleep-inducing peptide)?
DSIP is a nine-amino-acid neuropeptide first isolated in the 1970s and named for its association with delta-wave sleep in early animal experiments. It is studied for possible roles in sleep regulation, stress response, and neuroendocrine modulation, though its precise mechanism remains incompletely defined.
What is DSIP studied for beyond sleep?
In addition to sleep research, DSIP has been examined in models involving stress, pain, thermoregulation, and neuroendocrine function, reflecting a broad and not fully explained profile. Reviews describe it as a multifunctional peptide, which is part of why its mechanism is still debated.
What does DSIP's short half-life imply for research design?
DSIP is reported to have a serum half-life on the order of only several minutes and limited in vitro stability. This short exposure, combined with the observation that effects may involve carrier-protein complexes or precursor forms, is an important consideration when timing sleep-related endpoints in studies.
What is Pinealon (EDR)?
Pinealon is a synthetic tripeptide with the sequence Glu-Asp-Arg (EDR), part of the Khavinson family of short peptide bioregulators developed in St. Petersburg. It is studied in preclinical models for neuroprotective and gene-regulatory effects on neuronal cells.
What is the proposed mechanism of Pinealon?
Ultra-short peptides like Pinealon are hypothesized to act not through cell-surface receptors but by penetrating cells and interacting with DNA regulatory regions to modulate gene expression. In preclinical reports EDR is described as activating expression of proteins that support neuronal function and reducing apoptosis.
What is a peptide bioregulator?
Peptide bioregulator is the term used by the Khavinson research group for very short peptides (typically two to four amino acids) proposed to regulate tissue-specific gene expression. This framework is described in their published reviews, though it remains outside mainstream mechanistic consensus and rests largely on their own body of work.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.